Page 138 - Read Online

Fatourou et al. Hepatoma Res 2018;4:63 I http://dx.doi.org/10.20517/2394-5079.2018.62 Page 11 of 11

Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podesta LG, Gadano A, Boin IS, Duvoux C, Silva M. Liver transplantation for
hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016;36:1657-67.
28. Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F,
Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato
G, Cillo U. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: a multicenter cohort study
using the alpha-fetoprotein model as a survival predictor. Liver Transpl 2015;21:1250-8.
29. Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-Uso T, Quintini C, Eghtesad B, Fung JJ, Aucejo FN, Miller CM. Development and
validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort
analysis. Lancet Gastroenterol Hepatol 2017;2:595-603.
30. Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, Agostini A, Giovagnoni A, Vivarelli M, Lerut J. A novel prognostic index in
patients with hepatocellular cancer waiting for liver transplantation: time-radiological-response-alpha-fetoprotein-inflammation (TRAIN)
score. Ann Surg 2016;264:787-96.
31. Introduction to patient selection and organ allocation policies. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-
corp/4955/introduction_to_selection_and_allocation_policies.pdf. [Last accessed on 30 Aug 2018]
32. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular
carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22.